UAE ministry recalls medical products for pain relief, heart failure

Health facilities and healthcare professionals have been asked to suspend the use of the products

  
A worker wears a face mask as he buys medicine from a pharmacy, during the 24 hour lockdown to counter the coronavirus (Covid-19) outbreak in Dubai, United Arab Emirates April 6, 2020.

A worker wears a face mask as he buys medicine from a pharmacy, during the 24 hour lockdown to counter the coronavirus (Covid-19) outbreak in Dubai, United Arab Emirates April 6, 2020.

REUTERS/Ahmed Jadallah

UAE - The Ministry of Health and Protection (MoHAP) has withdrawn several medical products due to non-compliance with specifications. The ministry has also informed all health facilities and healthcare professionals to suspend the use of the products.

Salonpas Patch 2, used for temporary muscle pain relief, was one of the products withdrawn for non-compliance with approved specifications. According to the ministry circular, the amount of methyl salicylate in the product decreased after 12 months from production. There is no health risk and there are no reports of side effects caused by this problem. However, the ministry has recommended that manufacturers withdraw the affected product group from the public and private health sector.

In another circular, the Ministry of Health announced the withdrawal of Milrinone Lactate Injection 1mg / ml, 10ml, due to a defect in the quality of batch No. 1419020. Though the product was registered, the ministry has asked all healthcare practitioners not to use the batch. Pharmacies that have the stock should stop selling it and return it to the supplier.

In the same context, the Ministry informed all health facilities and healthcare practitioners to withdraw a number of AMS 700 products, including the MS Pump products, after receiving many complaints about the activation of the device. The Ministry said that the product was not registered with the Drug Administration at the Ministry of Health.

The ministry added that doctors can continue to use the product in clinical practice if no defect was found.

The Ministry of Health has also ordered the withdrawal of a Dextin 4mg/ml injection product, due to the defective quality of the MV2D35 batch.

In another circular, the ministry has also withdrawn the use of all ZERBAXA pharmaceutical products, used in treating infections caused by microbes, as the product does not meet the required specifications.

 

Copyright © 2021 Khaleej Times. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Risk